Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Ex vivo drug sensitivity testing in Korean AML patients: Integration of functional and genomic profiles for predicting clinical response and survival

View Full Paper
Ask AI
Bookmark
Share

Authors

HYHyoju YiSHSeunghyeok HamSPSesun Park

Discussion

Loading...

Member takes

Overview

Feasibility study shows ex vivo drug sensitivity testing improves treatment response predictions in Korean AML patients, highlighting the role of genomics.

Key Points

  • Drug responses demonstrated variability in acute myeloid leukemia patients, indicating tailored treatment may enhance outcomes.
  • Significant associations between TP53 mutations and drug resistance patterns were uncovered, particularly affecting venetoclax effectiveness.
  • Evaluation using ex vivo drug sensitivity testing, alongside genomic data, revealed novel drug–mutation relationships in AML.
  • Integrating functional profiles with genomics supports precision oncology strategies, warranting further validation in larger cohorts.

Cite This Study

Yi et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcachttps://doi.org/10.1182/blood-2025-939
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Multiomics-guided ex vivo drug sensitivity testing in Relapsed/Refractory Acute Myeloid Leukemia2025
  2. 2A rapid gene expression profiler predicts tumor responsiveness and patient outcome for standard-of-care therapies in acute myeloid leukemia2025 · 1 citations
  3. 3The transition from myelodysplastic neoplasm to secondary acute myeloid leukemia is revealed by molecular analysis, while functional drug screening demonstrates novel sensitivity patterns with clinical implication2025
  4. 4Functional drug response profiling predicts clinical outcomes and shows utility for treatment stratification in AML2025
  5. 5Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3-TKD - a multicenter retrospective study2025